Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Perfinity and Thermo Fisher Scientific Sign Co-Marketing Agreement

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
The agreement will see the companies co-market an automated protein sample preparation and analysis system.

This solution combines Perfinity's automated sample preparation platform with Thermo Fisher Scientific's liquid chromatography and mass spectrometry instrumentation. There are applications in biopharmaceutical process monitoring, protein drug development and biomarker discovery.

"Pharmaceutical manufacturers cannot wait for 24 hours to monitor the purity of each batch of protein-based product," said Robert Ellis, Perfinity Biosciences CEO. "When proteins oxidize, things can go bad quickly, and this is very costly. We developed our automated sample preparation platform to generate results quickly enough to let customers protect the value of each batch before it's too late. Now, with the Thermo Scientific LC and MS instruments, we offer a complete system from automated sample preparation through data reporting."

"A major goal at Thermo Fisher is to create efficiency and productivity throughout the biopharmaceutical value chain, and Perfinity's approach to in-process analysis meshes nicely with these plans," said Patrick Bennett, Thermo Fisher director of marketing, pharmaceutical industry.

Perfinity's sample preparation platform is an automated system that reduces the time required for the trypsin digestion step prior to mass spec analysis from approximately 18 hours using conventional techniques to less than two minutes. The proprietary three-column system is based on the company's trypsin columns, and also includes an automated workstation and software. Thermo Fisher is providing Thermo Scientific UltiMate 3000 UHPLC systems and a choice of Orbitrap-based hybrid or triple quadrupole mass spectrometers depending on customers' specific requirements.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!